

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

[Ablynx](#)

RRID:SCR_002940

Type: Tool

Proper Citation

Ablynx (RRID:SCR_002940)

Resource Information

URL: <http://www.Ablynx.com>

Proper Citation: Ablynx (RRID:SCR_002940)

Description: A biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases including inflammation, hematology, oncology and pulmonary disease.

Abbreviations: Ablynx

Resource Type: reagent manufacture, production service resource, material service resource, service resource

Keywords: nanobody, protein, antibody fragment, human disease, oncology, hematology, tumor, blood, therapy, therapeutic, pharmaceutical, drug product, drug

Related Condition: Inflammation, Cancer, Pulmonary disease, Thrombosis, Alzheimer's disease, Rheumatoid arthritis, Osteoporosis, Thrombotic thrombocytopenic purpura, Respiratory syncytial virus

Resource Name: Ablynx

Resource ID: SCR_002940

Alternate IDs: nif-0000-30052

Record Creation Time: 20220129T080216+0000

Record Last Update: 20260805T044046+0000

Ratings and Alerts

No rating or validation information has been found for Ablynx.

No alerts have been found for Ablynx.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Coddens A, et al. (2020) An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics. Journal of immunological methods, 487, 112896.

Bauché D, et al. (2020) Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions. Journal for immunotherapy of cancer, 8(2).

Weiss RA, et al. (2019) Nanobodies that Neutralize HIV. Vaccines, 7(3).

Kazemi-Lomedasht F, et al. (2018) Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function. Iranian journal of basic medical sciences, 21(3), 260.

Veugelen S, et al. (2017) Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins. Methods in enzymology, 584, 59.

Arbabi-Ghahroudi M, et al. (2017) Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. Frontiers in immunology, 8, 1589.

Van Audenhove I, et al. (2016) Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer. EBioMedicine, 8, 40.

Zhu M, et al. (2014) Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. Journal of translational medicine, 12, 352.

Elvin JG, et al. (2013) Therapeutic antibodies: market considerations, disease targets and bioprocessing. International journal of pharmaceuticals, 440(1), 83.

Boruah BM, et al. (2013) Single domain antibody multimers confer protection against rabies infection. PloS one, 8(8), e71383.

Elsadek B, et al. (2012) Impact of albumin on drug delivery--new applications on the horizon. Journal of controlled release : official journal of the Controlled Release Society, 157(1), 4.

Kratz F, et al. (2012) Clinical impact of serum proteins on drug delivery. *Journal of controlled release : official journal of the Controlled Release Society*, 161(2), 429.

Wesolowski J, et al. (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. *Medical microbiology and immunology*, 198(3), 157.

Dimitrov DS, et al. (2009) Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? *Methods in molecular biology (Clifton, N.J.)*, 525, 1.

Saerens D, et al. (2008) Single-domain antibodies as building blocks for novel therapeutics. *Current opinion in pharmacology*, 8(5), 600.

Hmila I, et al. (2008) VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin Aahl'. *Molecular immunology*, 45(14), 3847.

Harmsen MM, et al. (2007) Properties, production, and applications of camelid single-domain antibody fragments. *Applied microbiology and biotechnology*, 77(1), 13.